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Simple Summary: The ability of the immune system to kill tumour cells is a natural and extremely
effective defence mechanism for fighting cancer. Cytotoxic-T-cells are a critical component of our
immune system which function is to eliminate cancer cells. In some cancers, especially those
with a rich tumour stroma, these cytotoxic-T-cells are unable to reach and kill the tumour cells.
Cancer-associated fibroblasts are the most abundant cells in the tumour stroma and play a key role of
the recruitment, infiltration and function of cytotoxic T-cells in the tumour, via several molecular
mechanisms which we describe in this review.
Abstract: The tumour microenvironment (TME) is the complex environment in which various
non-cancerous stromal cell populations co-exist, co-evolve and interact with tumour cells, having a
profound impact on the progression of solid tumours. The TME is comprised of various extracellular
matrix (ECM) proteins in addition to a variety of immune and stromal cells. These include
tumour-associated macrophages, regulatory T cells (Tregs), myeloid-derived suppressor cells, as well
as endothelial cells, pericytes and cancer-associated fibroblasts (CAFs). CAFs are the most abundant
stromal cell population in many tumours and support cancer progression, metastasis and resistance
to therapies through bidirectional signalling with both tumour cells and other cells within the TME.
More recently, CAFs have been shown to also affect the anti-tumour immune response through direct
and indirect interactions with immune cells. In this review, we specifically focus on the interactions
between CAFs and cytotoxic CD8+ T cells, and on how these interactions affect T cell recruitment,
infiltration and function in the tumour. We additionally provide insight into the therapeutic
implications of targeting these interactions, particularly in the context of cancer immunotherapy.
Keywords: CAF; cytotoxic T cell; T cell recruitment; T cell infiltration; T cell function
1. Introduction
Our understanding of the so-called tumour microenvironment (TME) has seen significant
advancement through a large number of studies conducted over the last decade [1–7]. The TME
describes the entirety of the components within the tumour mass, such as infiltrating immune cells
and non-malignant stromal cells, in addition to the malignant cells themselves.
Cancer-associated fibroblasts (CAFs) are the dominant stromal cell population in many solid
tumours [8–10] and form the focus of the present review. CAFs exhibit several functions in cancer:
promoting malignant cell growth through bidirectional signalling with both tumour cells and other
cells within the TME [11,12]; facilitating the process of metastasis through synthesis and remodelling of
extracellular matrix (ECM) components and secretion of angiogenic factors such as vascular endothelial
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growth factor (VEGF) [11,13]; sustaining cancer cell bioenergetics through release of CAF-derived
metabolites [14,15]; contributing to tumour chemoresistance [3,16]; and promoting evasion of immune
surveillance [17,18].
However, despite the variety of CAF-mediated tumour-promoting functions, CAF ablation
strategies have largely been deemed as deleterious. This was exemplified by the landmark studies
of Özdemir et al. [19] and Rhim et al. [20], in which genetic depletion of CAFs in murine models of
pancreatic ductal adenocarcinoma (PDAC) resulted in more aggressive tumours and worse survival
outcomes. These findings are in contrast to other studies which have shown a beneficial effect of
the genetic ablation of fibroblast activation protein (FAP+) CAFs on survival outcomes in preclinical
models of PDAC and Lewis lung carcinoma [21,22]. It should be noted, however, that other studies
have reported severe systemic toxicities such as cachexia and reduced erythropoiesis in transgenic
models of PDAC and transplantable models of colorectal carcinoma upon genetic ablation of the
FAP+ CAF population [23]. Therefore, the translational relevance of large-scale targeting of the CAF
population remains an area of close contention.
What has been made clear through these studies is that there is significant phenotypic heterogeneity
within the CAF population with certain subtypes acting to restrain, rather than promote tumour
progression [24]. There is now a large body of work seeking to delineate the roles of these different CAF
subtypes within the TME but this is not the topic of the present review. Identification of unfavourable
CAF subpopulations will be paramount when it comes to the design of therapeutics that selectively
target these tumour supporting CAFs.
However, whilst our understanding of CAF heterogeneity has improved over the last half decade,
CAF subtyping is still very much in its infancy and identifying unique CAF markers of CAF subtypes
has proven to be a significant challenge in the field of cancer biology. At this early stage, it is currently
unknown whether this subtyping of CAF populations will confer therapeutic benefit. We believe
therefore, that it is important to also further characterise the functional interactions of CAFs within
the TME, alongside approaches to delineate CAF heterogeneity, for the rational design of therapeutic
strategies that target the pro-tumourigenic functions of CAFs.
Studies conducted in recent years have developed a greater appreciation for the role of the immune
system in regulating/deregulating cancer progression. This has also led to a surge of interest in the
field of immuno-oncology, with immunotherapeutic strategies such as adoptive transfer of chimeric
antigen receptor (CAR) T cells and immune checkpoint inhibitors (ICIs) being the subject of a large
number of clinical trials over the last decade. Critically, in the context of solid tumours, the efficacy
of these immunotherapeutic strategies is dependent on a functional cytotoxic CD8+ T cell response
within the TME [25,26]. Given that CAFs are one of the principle components of the TME in many
malignancies and with the current efforts being made to improve cancer immunotherapy, the present
review will focus specifically on how CAFs affect cytotoxic CD8+ T cell recruitment, infiltration and
function within the tumour. Additionally, we shall explore the implications of targeting CAF-T cell
interactions for cancer immunotherapy, seeking to restore CD8+ T cell cytotoxic activity and promote
an effective anti-tumour immune response.
2. CAFs and T Cells
The cancer immunity cycle proposed by Chen and Mellman describes a series of stepwise events
implicit to an effective anti-tumour T cell response [27]. Critically, the efficacy of cancer immunotherapy
is reliant on all stages of this cycle being intact. CAFs are able to inhibit the function of CD8+ T cells,
reducing their tumour killing capacity, through interference with several stages of the cancer immunity
cycle. In particular, CAFs have been shown to abrogate CD8+ T cell function through: deregulation of
T cell trafficking/recruitment to the tumour; reducing T cell infiltration into the TME; and suppression
of the cytotoxic function of T cells which are present within the tumour milieu (Figure 1, Table 1).
The present review will provide an updated summary of the literature concerning CAF-mediated
deregulation of CD8+ T cell activity through these three main mechanisms.
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Given the fact that CD8+ T cells directly mediate tumour cell killing and their importance in the
field of immuno-oncology, the literature detailed herein is specifically focused on the effects of CAFs
on cytotoxic CD8+ T cells. Nonetheless, it should be mentioned that the pleiotropic functions of CAFs
extend also to regulating the activity of other T lymphocytes such as regulatory T cells (Tregs) and
CD4+ T helper cells and other immune cell populations present in the tumour microenvironment [28].
3. CAFs Mediated Inhibition of CD8+ T Cell Trafficking/Recruitment
The ability of the immune system to mount a successful response relies, in part, on the recruitment
of various immune cells to the site of inflammation. This recruitment is dependent on a highly
sophisticated system involving chemokines and their corresponding chemokine receptors, enabling a
highly specific and localised immune response. Accordingly, upon their activation within the TME,
CAFs can modulate the recruitment of peripheral CD8+ T cells towards the tumour through secretion of
numerous cytokines and chemokines. For instance, activated CAFs are able to promote the trafficking
of CD8+ T cells away from the juxta-tumoral compartment and towards the pan-stromal compartment
of PDAC tumours in a chemokine-dependent manner [29]. The juxta-tumoral compartment describes
the area immediately adjacent to the tumour cells themselves, whereas the panstromal compartment
represents areas non-adjacent to the tumour. The resulting low juxta-tumoural CD8+ T cell infiltrate is
an adverse indicator of prognosis in the context of human PDAC. Mechanistically, CAF-secretion of
C-X-C motif chemokine 12 (CXCL12) guides peripheral CD8+ T cell migration towards activated CAFs
located in the stromal regions surrounding the tumour. This leads to the sequestration of CD8+ T cells
in the pan-stromal compartment and reduced migration into tumour islets. Notably, flow cytometric
analysis revealed a greater expression of the CXCR4 (the receptor for CXCL12) on circulatory CD8+ T
cells from PDAC patients compared to healthy donors [29]. Corroborating this observation, preclinical
studies in an autochthonous murine model of PDAC revealed that both pharmacological inhibition of
CXCR4 and genetic ablation of CXCL12 producing CAFs led to a rapid accumulation of CD8+ T cells
within the tumour and reduced tumour growth [30]. A recent study investigating the heterogeneity
of stromal cell populations in triple-negative breast cancer (TNBC) patients and utilising single cell
RNA-sequencing, revealed the presence of an inflammatory CAF (iCAF) subpopulation [31]. Of note,
these iCAFs displayed a strong upregulation of the CXCL12-CXCR4 chemoattractant pathway genes,
and the authors demonstrated a strong association of CD8+ T cell dysfunction and exclusion with
iCAF presence [31].
4. CAF-Mediated Regulation of CD8+ T Cell Infiltration in Tumours
A key hallmark of activated CAFs is their ability to aberrantly deposit extracellular matrix (ECM)
proteins such as collagen, fibronectin, hyaluronan, in addition to matrix degradation enzymes [32].
This deregulation of the ECM has long been known to facilitate excessive tumour growth, invasion and
metastasis [33,34]. More recently, CAF-mediated deregulation of the ECM has been implicated in the
modulation of immune cells, and in particular, CD8+ T cells, within the TME. The ability of CD8+ T
cells to recognise tumour cells and exert a cytotoxic effect requires the physical interaction between the
CD8+ T cells and the tumour cells. Hence, appropriate localisation and migration of CD8+ T cells
towards the tumour cells within the TME is an essential prerequisite for effective T-cell mediated killing
of tumour cells. Various studies have shown an implicit role for CAFs in modulating T cell infiltration
into, and within the TME. Using a live cell imaging approach in viable slices of human lung tumours,
a study revealed that CAFs are able to reduce the infiltration of CD8+ T cells into tumour islets,
through biophysical deregulation of ECM components [35]. CD8+ T cells were found to preferentially
accumulate within the stromal regions of these tumours, which are characterised by a far “looser”
network of fibronectin and collagen fibers, as opposed to accumulating within tumour islets, which are
encapsulated in dense networks of collagen and fibronectin parallel fibres [35]. Matrix oosening
through collagenase treatment led to an increased infiltration of CD8+ T cells into tumour islets, with a
twofold increase in the number of T cells in contact with tumour cells. Furthermore, this same group
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went on to corroborate these findings in the context of ovarian cancer, utilising the same live cell
imaging approach, with CD8+ T cells accumulating within the loose-collagen regions [36]. Similarly,
analysis of human PDAC tissues has revealed that high tumour activation of focal adhesion kinase
(FAK) correlates with a greater deposition of CAF-derived collagen 1, which culminates in a reduced
number of tumour infiltrating CD8+ T cells and predicts a poor clinical outcome [37]. Importantly,
both genetic and pharmacological inhibition of FAK1 in transgenic murine models of PDAC resulted
in decreased levels of fibrosis and increased T cell infiltration. This was exemplified by a reduction in
collagen deposition and numbers of both total and proliferating FAP+ and α-smooth muscle action
(αSMA+) CAFs, in addition to a near 5-fold increase in CD8+ T cell infiltration into PDAC tissue [37].
In corroboration with these findings, other studies have shown that CD8+ T cells preferentially
accumulate in areas of low collagen density [38]. 3D-invasion assays revealed that high-density
collagen matrices significantly reduce the migration distance and number of invading CD8+ T cells
in in vitro models of PDAC, impeding T cell-tumour cell contact [38]. Similarly, other studies have
shown that T cells cultured in 3D high-density collagen matrices display a reduced cytotoxic potential
in patient derived models of melanoma [39]. This collagen-density dependent reduction in cytotoxic
activity also coincided with a reduced secretion of interferon gamma (IFNγ). This study additionally
utilised whole-transcriptome RNA-seq analysis to reveal that T cells cultured in high-density collagen
matrices downregulate markers of cytotoxic activity whilst upregulating markers indicative of a Treg
phenotype [39]. Overall, these data suggest that CAF reorganisation of the ECM architecture can act
as a biophysical barrier to T cell accumulation within the tumour parenchyma, reducing the T-cell
contact-dependent killing of tumour cells in different solid malignancies.
Conversely, several lines of evidence from a series of independent studies may call into question
the importance of CAF-mediated ECM deregulation as a means of reducing T cell infiltration.
Utilising novel computational imaging techniques, one study showed that while spatial distribution of
CD8+ T cells in close proximity with tumour cells correlated with an increased overall patient survival
in pancreatic cancer, the density of collagen 1 deposition and number of αSMA+ CAFs do not correlate
with a reduced CD8+ T cell infiltrate [40]. In contrast to previous reports, this study showed that
tumours with a greater paucity of CD8+ T cells actually exhibited diminished collagen 1 deposition
in their surrounding milieu [40]. This suggests that collagen deposition and ECM remodelling may
favour, rather than hinder, the process of T cell infiltration within the TME. This notion is supported by
another study analysing the immune cell infiltrate of human PDAC specimens. Immunohistochemistry
analysis revealed a significantly higher infiltration of CD8+ T cells in patients with a high stromal
density compared to patients with a loose or moderate stromal density [41]. In agreement with these
findings, a histological analysis of human colorectal carcinomas also showed that increased deposition
of collagen and a greater desmoplastic reaction correlated with increased numbers of tumour infiltrating
CD8+ T cells [42].
Therefore, at least in the context of PDAC and colorectal carcinoma, it still remains unclear
whether CAF-mediated ECM deposition impedes or favours infiltration of CD8+ T cells into the
tumour. CAFs have also been shown to negatively regulate the infiltration of CD8+ T cells into
solid tumours through regulation of their secretome. Increased secretion of CAF-derived TGF-β
has been shown to correlate with a reduced accumulation of CD8+ T cells within both metastatic
urothelial cancer and metastatic colorectal carcinoma and a reduced response to immune checkpoint
inhibitors [43,44]. In both settings, inhibition of CAF-derived TGF-β resulted in increased T cell
accumulation within the tumour parenchyma and restored the efficacy of checkpoint inhibition in
preclinical models, reducing metastatic burden [43,44]. Currently, however, the precise mechanisms
through which TGF-β modulates the infiltration of CD8+ T cells to these tumours remain elusive.
It is important to also note the role of tumour hypoxia as another factor responsible for the
reduced infiltration of CD8+ T cells in many solid tumours. CAF deposition of ECM contributes
to the generation of a hypoxic TME, and in turn, the CAFs upregulate the expression of angiogenic
factors such as VEGF [45,46]. Endothelial cells downregulate the expression of various cell adhesion
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molecules such as ICAM-1/2 and VCAM-1 in response to VEGF, a process known as “endothelial cell
anergy” [47]. A reduction in cell adhesion molecules inhibits the extravasation of circulatory CD8+
T cells through the tumour vasculature and into the tumour itself, and studies have shown that a
targeted reduction of hypoxia can restore the infiltration of T cells in preclinical models of prostate
cancer [48]. The pleiotropic effects of hypoxia on the TME and the implications for cancer development
and progression have been recently reviewed [49–51].
5. CAF-Mediated Suppression of T Cell Cytotoxic Function
5.1. Direct Upregulation of Immune Checkpoint Molecule Expression
The immune system is well-orchestrated and in a healthy organism exists in a state of homeostasis.
The immune system can be rapidly mobilised to act against invading pathogens or neoplastic cells
whilst simultaneously, self-tolerance is maintained by negative regulation of cell activation—preventing
the indiscriminate killing of host cells, as seen in autoimmune disorders [52]. Immune checkpoint
molecules are a group of co-inhibitory and co-stimulatory molecules which serve to maintain this
critical state of homeostasis. In the context of many cancers, chronically activated tumour reactive T
cells are often dysfunctional or “exhausted” due to the activation of inhibitory immune checkpoint
receptors, displaying a loss of effector function and proliferative potential [53–57]. CAFs can directly
induce this exhausted phenotype in T cells through upregulation of a host of immune checkpoint
ligands on their cell surface. For instance, fibroblasts derived from melanoma patient biopsies displayed
an upregulation of both programmed death ligands 1 and 2 (PD-L1 and PD-L2), which bind to the
PD-1 receptor, directly abrogating CD8+ T cell function [58]. More recently, both PD-L1 and PD-L2
have been shown to be upregulated in CAFs isolated from pancreatic cancer patients undergoing
surgical resection [59]. This same study also demonstrates a role for pancreatic CAFs in promoting
the expression of co-inhibitory immune checkpoint receptors in proliferating T cells, such as PD-1;
T-cell immunoglobulin and mucin-domain containing-3 (TIM-3); lymphocyte-activation gene- 3
and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), contributing to T cell dysfunction [59].
However, the underlying mechanism(s) through which CAFs promote the upregulation of inhibitory
immune checkpoints on CD8+ T cells is incompletely understood. Albeit the authors show that no
difference in immune checkpoint expression exists between CD8+ T cells grown in direct co-culture
with CAFs, and those separated by transwell cultures [59]. This suggests that the upregulation of
inhibitory immune checkpoints is mediated through CAF secretion of soluble factors. Importantly,
high expression of PD-1 on tumour-infiltrated lymphocytes is also widely known as an adverse
indicator of prognosis in PDAC [60]. Interestingly, recent studies have shown that CAFs isolated from
murine lung adenocarcinomas and melanoma tumours can directly induce apoptosis in tumour-specific
CD8+ T cells through simultaneous upregulation of PD-L2 and Fas ligand, leading to increased tumour
survival [61]. Strikingly, this study also shows that certain CAFs may also be able to participate in
antigen presentation, leading to direct killing of tumour-reactive CD8+ T cells in an antigen-specific
manner through engagement of PD-L2 and Fas ligand [61].
5.2. Indirect Upregulation of Immune Checkpoint Molecule Expression
In addition to upregulation of immune checkpoint molecules on their own cell surface, CAFs can
also act indirectly through paracrine signalling interactions to upregulate the expression of immune
checkpoint molecules on both tumour cells and other cells of the TME. For instance, CAF-derived
CXCL5 was shown to upregulate the expression of PD-L1 in murine melanoma and colorectal carcinoma
cell lines upon activation the CXCR4 in a PI3K-AKT-dependent manner [62]. Similarly, patient-derived
hepatocellular carcinoma CAFs were shown to upregulate the expression of PD-L1 on the surface of
neutrophils, another prominent component of the TME, through secretion of IL-6 and activation of a
STAT3-dependent signalling pathway [63]. In addition, these CAF-primed neutrophils were then able
to suppress T cell proliferation and production of IFNγ in a PD-L1-dependent manner [63].While less
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is known about CAF induction of immune checkpoint expression on other cells of the TME, it is
important to note that CAFs mediated deregulation of CD8+ T cell function is not limited to direct
interactions between these two cell types.
5.3. T Cell Suppression through CAF Metabolic Reprogramming
The role of CAF metabolic reprogramming in promoting tumour progression and contributing
to therapeutic resistance has now been well established. For instance, paracrine transfer of CAF
metabolites such as deoxycytidine to tumour cells contributes to gemcitabine resistance in the context of
PDAC [64]. A more comprehensive overview of CAF metabolic reprogramming in cancer can be found
in several recent review articles [65,66]. Accumulating evidence has now revealed that CAF metabolic
reprogramming serves as another mechanism for the suppression of cytotoxic T cell function within the
TME. For example, tumour-educated mesenchymal stromal cells (MSCs) isolated from human cervical
cancer (CeCa) patients were shown to suppress the proliferation, activation, and effector functions of
CD8+ T cells through production of purinergic nucleosides [67]. Bone-marrow-derived MSCs are one
of the progenitor populations which give rise to CAFs [68,69], of which there are many functionally
and phenotypically diverse cellular sources [70]. Mechanistically, CeCa-derived MSCs were shown to
upregulate the expression of the ectonucleotidases CD39 and CD73, which catalyse the generation
of the immunosuppressive nucleoside adenosine through hydrolysis of ATP, ADP, and AMP [67].
Adenosine then exerts its inhibitory effect on cytotoxic T cell activity through binding to the A2A
receptor [67]. The role of adenosine in regulating tumour immunity and a summary of recent clinical
strategies to therapeutically target this pathway has been recently reviewed [71].
Another example of T cell suppression caused by CAF metabolic reprogramming has recently
been observed using CAFs derived from prostate cancer patients [72]. This study identifies glycolytic
CAFs as a major source of extracellular lactate, at least in the context of prostate cancer, with the
immunosuppressive effects of lactic acidosis on cytotoxic T cell activity within the TME being well
documented [73–76]. In addition, it has been shown that CAF expression of the enzyme arginase II is
able to inhibit the infiltration and proliferation of T cells in the context of pancreatic cancer, acting as
an indicator of poor prognosis [77]. Sufficient levels of extracellular arginine are crucial for T cell
activation and proliferation [78]. Therefore, an increased expression of CAF arginase II leads to a
reduced concentration of arginine within the TME, due to an increased hydrolysis of arginine to
ornithine and consequently, a decrease in T cell proliferation and cytotoxic function.
5.4. Interference with Antigen Presentation and T Cell Activation
Cross-presentation of tumour-specific antigens by antigen-presenting cells (APCs) such as dendritic
cells (DCs) is critical for the generation of antigen-specific T cells and a sustained anti-tumour immune
response. The release and cross-presentation of tumour antigens to prime CD8+ T cells is the integral
step in the initiation of the “Cancer Immunity cycle” described by Chen and Mellman [27]. Therefore,
interference with antigen presentation and/or suppression of professional APCs can indirectly suppress
the cytotoxic function of CD8+ T cells. In this regard, recent studies have shown that CAFs are
able to interfere with various aspects of DC biology, including maturation and trafficking through
the secretion of several factors. For instance, through secretion of IL-6, CAFs derived from human
hepatocellular carcinoma are able to upregulate the activation of the STAT3 signalling pathway in
DCs, which in turn, induces a regulatory DC phenotype which is unable to prime and activate T
cells [79]. In comparison to normal mature DCs, the CAF-educated regulatory DCs were shown to have
a reduced expression of antigen-presenting and co-stimulatory molecules (CD1a, HLA-DR, CD80 and
CD86). As a result, CD8+ T cells were functionally impaired, displaying both a lower expression of
IFNγ and a lower proliferative potential when grown in co-culture with regulatory DCs [79]. Of note,
other studies have shown that T-cell-conditioned media are able to upregulate IL-6 production in CAFs
isolated from lung tumour biopsies [80]. While these observations were made in separate cancer types,
this highlights an example of reciprocal signalling between these two cell types and further studies
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should ascertain whether a negative feedback mechanism is in place, involving T cell secretory factors,
subsequent release of IL-6 by CAFs and finally, induction of the regulatory DC phenotype.
Table 1. Summary of CAF-derived molecules/factors responsible for the inhibition of CD8+ T cells
through interference with T cell-trafficking/recruitment, infiltration and cytotoxic function.
CAF Derived
Molecule
Effect on CD8+
T Cells Tumour Type/Model
Type of Analysis
Performed Result of Study Reference
CXCL12
Decreased
recruitment.
CD8+ T cells
sequestered in
panstromal
compartment
Pancreatic cancer.
TMA analysis of patient
tissue. Transgenic KPC
murine model.
In vitro migration assays
utilising circulatory
patient derived
CD8+ T cells.
Tissue microarray
analysis of patient
tissues and IHC analysis
of KPC tumours.
Migration assays
assessed differential
migration of CD8+ T
cells towards activated
pancreatic stellate cell
(aPSC) conditioned
media (CM).
Lower CD8+ T cells in
juxtatumoral
compartment.
CD8+ T cells migrate
preferentially towards
aPSC CM. Knockdown
of CXCL12 = reduced
CD8+ T cell migration
Ene-Obong
et al., 2013 [29]
TGF-β
Decreased
infiltration +
reduced
response to
immune
checkpoint
inhibitors
mUC and breast cancer.
Transcriptome RNA-seq
of mUC patient tissue.
Syngeneic orthotopic
transplantation of EMT6
murine breast
cancer cells.
RNA-sequencing of 298
tissue samples, derived
from mUC patients
treated with anti-PD-L1
therapy.
Flow cytometric and
quantitative IHC
analysis of EMT6
tumours. Mice treated
with single
agent/combination
treatment anti-PD-L1
and anti-TGF-β.
Lack of response to
anti-PD-L1 associated
with low CD8+ T cell
infiltration and a
signature of TGF-β
signalling in fibroblasts.
Reduced tumour burden
and increased CD8+
infiltration a under
combinatory anti-PD-L1
and anti-TGF-β
treatment.
Mariathasan
et al., 2018 [43]
Collagen and
fibronectin
Decreased
infiltration
Lung cancer.
Live imaging of viable
human lung
cancer slices.
2-photon imaging and
second harmonic
generation (SHG) +
immunostaining, to
visualise collagen and
fibronectin density.
Reduced infiltration of
CD8+ T cells in regions
of dense
collagen/fibronectin.
Salmon et al.,
2012 [35]
Pancreatic cancer.
Analysis of patient tissue.
Pancreatic cancer
IHC analysis of PDAC
patient tissue using
picrosirius red to
measure collagen
deposition.
Activation of FAK1 =
increased deposition of
collagen and reduced
numbers of tumour
infiltrating CD8+ T cells.
Jiang et al.,
2016 [37]
3D-in vitro
invasion assays
Brightfield microscopy
assessed depth of T cell
migration into collagen
matrices of varying
densities containing
SDF-1 (CXCL12) as
chemoattractant.
Higher density collagen
matrices impeded
invasion of T cells
towards SDF-1.
Hartmann
et al., 2014 [38]
PD-L1 and
PD-L2
Suppression
through direct
CAF upregulation
of immune
checkpoint
expression
Melanoma.
In vitro co-cultures
using patient biopsy
derived CAFs
T cell function assessed
by measuring IFN-γ in
co-cultures with
melanoma patient
derived CAFs. CAF
expression of PD-L1 and
PD-L2 assessed by
flow cytometry.
IL-1 treated melanoma
CAFs led to reduced T
cell production of IFN-γ
in co-cultures and
increased CAF
expression of both PD-L1
and PD-L2.
Khalili et al.,
2012. [58]
PD-L2 and
FasL
Suppression of
activity + direct
induction
apoptosis.
Lung cancer and
melanoma.
CAFs isolated from
genetically engineered
LSL mouse model of
lung cancer and
syngeneic orthotopic
transplantation of
B16.F10 melanoma cells.
Co-culture cytotoxicity
assays with CAFs from
lung/melanoma tumours
and ovalbumin-specific
OT-I T cells, and
OVA-expressing tumour
cells. Analysed by flow
cytometry.
CAF-conditioned OT-I T
cells display reduced
tumour killing capacity.
CAFs cause
antigen-dependent
decrease in OT-I T cell
viability due to increased
expression of PD-L2
and FasL
Lakins et al.,
2018. [61]
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Table 1. Cont.
CAF Derived
Molecule
Effect on CD8+ T
Cells Tumour Type/Model
Type of Analysis
Performed Result of Study Reference
CXCL5
Suppression
through induction
of PD-L1
expression in
tumour cells
Melanoma and
colorectal carcinoma.
In vitro models of
melanoma and colorectal
cancer cell lines, primary
CAFs from
subcutaneous xenograft
melanoma tumours
Co-culture assays of
tumour cell lines and
primary CAFs analysed
by flow cytometry.
qRT-PCR, IF and IB
reveal CXCL5
overexpression in CAFs.
Co-culture induced
overexpression of PD-L1
in tumour cells in
a CXCL5
dependent manner.
Li et al., 2019
[62]
IL-6
Suppression
through induction
of PD-L1
expression on
neutrophils.
Hepatocellular
carcinoma (HCC).
In vitro assays
neutrophils cultured in
HCC patient derived
CAF conditioned media.
Neutrophils cultured in
CAF-conditioned media
and analysed for
upregulation of PD-L1
by qRT-PCR and flow
cytometry. CAF-primed
neutrophils co-cultured
with purified peripheral
T cells.
HCC CAF-conditioned
media upregulates
expression of PD-L1 in
neutrophils in an IL-6
dependent manner.
CAF-primed neutrophils
suppress T cell
proliferation and
IFN-γ production.
Cheng et al.,
2018 [63]
Suppression through
generation of
immunosuppressive
regulatory DCs.
Hepatocellular
carcinoma.
In vitro co-culture assays
utilising CAFs derived
from HCC patient
tumour explants and
DCs differentiated from
healthy CD14+
monocytes.
IL-6 neutralising Abs
added to co-culture
systems. Analysis by
flow cytometry.
CAF-educated DCs
co-cultured with
peripheral blood
lymphocytes. Analysis
by flow cytometry.
CAF-educated DCs
exhibit more
immunosuppressive
(regulatory)phenotype.
Induction of this
phenotype is IL-6
dependent.
CAF-educated DCs
inhibit T cell
proliferation and CD8+
production of IFNγ.
Cheng et al.,
2016 [79]
CD39/CD73
Suppression
through increased
generation of
immunosuppressive
adenosine
Cervical cancer.
In vitro assays involving
patient-derived MSCs
and PBMC derived
CD8+ T cells.
MSC CD39/CD73
expression determined
by flow cytometry and
IHC. Ado containing
MSC conditioned media
added to CD8+ T cells,
proliferation determined
by colorimetric assay,
IFN-γ measured by
flow cytometry.
CD39/CD73 expression
confirmed and were
confirmed to hydrolyse
ATP, ADP and AMP to
form Ado. Ado
containing MSC
conditioned media
strongly inhibited
proliferation and
activation of
CD8+ T cells.
de Lourdes
Mora-García
et al., 2016
[67]
TGF-βi
(βig-h3)
Suppression
through blunting
TCR signal
transduction
Pancreatic cancer.
In vitro assays using
CAFs derived from
transgenic murine
models of PDAC. In vivo
syngeneic subcutaneous
transplantation of
transgenic murine
KC cells.
CD8+ T cells cultured in
CAF-conditioned media
(confirmed to contain
βig-h3 by ELISA) +/-
βig-h3 depleting
antibody. Proliferation
and expression of
exhaustion markers in
CD8+ T cells measured
by flow cytometry.
Confocal microscopy
used to determine
βig-h3 interaction with
CD61 on CD8+ T cells.
Flow cytometry used to
characterise effect of
βig-h3 depletion in vivo.
CAF-conditioned media
(confirmed to contain
βig-h3) caused reduced
proliferation of CD8+ T
cells and βig-h3
depletion reduced
expression of exhaustion
markers (PD-1, TIM-3).
Confocal microscopy
confirmed interaction
between βig-h3 and
CD61 (colocalization).
βig-h3 depletion in vivo
reduced tumour growth
and enhanced the
number of activated
CD8+ T cells.
Goehrig et al.,
2019 [81]
There is also evidence that CAFs may act directly on CD8+ T cells to interfere with the process
of antigen recognition and activation, through inhibition of the T cell receptor (TCR). Utilising both
in vitro and syngeneic orthotopic murine models of PDAC, a study showed a suppressive effect
of CAF-derived transforming growth factor beta-induced protein (TGF-βi) on the antigen-specific
activation of ovalbumin specific CD8+ T cells [81]. Mechanistically, TGF-βi secreted by CAFs binds to
CD61 on the surface of CD8+ T cells, driving binding of HIC-5 protein to Y505 phosphorylated Lck
and blunting TCR signal transduction [81,82]. This leads to reduced proliferation and activation of
antigen specific CD8+ T cells, whilst TGF-βi blocking antibody restored CD8+ T cell proliferation
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and reduced T cell exhaustion, characterised by reduced expression of PD-1 and TIM-3 in vitro [81].
Furthermore, antibody-mediated depletion of TGF-βi led to reduced tumour burden in spontaneously
developing murine models of PDAC and critically, these tumours were more highly infiltrated with
CD8+ T cells that expressed greater levels of granzyme B, IFNγ and TNFα [81].
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Finally, while the topic of CAF heterogeneity will be covered in greater detail in an ther eview in
this journal issue, recent evidence has revealed a novel subpopulation of CAFs with antigen-presenting
capabilities. These so-called “apCAFs” were found to express MHC class II at their cell surface,
whilst also possessing the capacity to present the ovalbumin peptide to CD4+ T cells ex vivo [83].
Co-stimulatory molecules such as CD80, CD86 and CD40 are utilised by professional APCs to elicit
the vital secondary signal necessary for T cell clonal expansion upon TCR ligation [84]. The absence
of these co-stimulatory markers within the “apCAF” population is particularly noteworthy, with the
authors postulating that the MHCII present on these cells acts as a decoy receptor, deactivating
CD4+ T cells either through induction of anergy or differentiation into immunosuppressive Tregs.
Future investigations into “apCAFs” are required to provide greater mechanistic insight into these
interactions; however, the implications are great. Increased Treg differentiation would unfavourably
offset the CD8+ to Treg ratio, which predicts a poor clinical outcome and poor response to therapeutics
in multiple types of cancer [85–87].
5.5. Therapeutic Strategies to Overcome CAF-Mediated Inhibition of CD8+ T Cells
Since the breakthrough approval of the immune checkpoint CTLA-4 inhibitor ipilimumab for
the treatment of metastatic melanoma in 2011, the field of clinical immuno-oncology has seen rapid
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development and a surge of interest. The success of ipilimumab represents an important proof of
concept for therapeutic modulation of the immune system, with CTLA-4 being the first target to bear
translational relevance. This has led to the emergence of new and improved checkpoint inhibitors
over the last decade, the use of which has been extended to an increasing number of indications
for widespread clinical benefit [88]. Immune checkpoint blockade represents a paradigm shift in
being able to harness the immune system to selectively target tumour cells which has also led to a
renewed interest into designing anti-cancer vaccines based on mutation-associated neoepitopes [89].
In addition to this, recent advancements into CRISPR-Cas9 technology have revolutionised the
generation of highly efficacious CAR-T cell-based therapies [90]. However, the success of all three
of these immunotherapeutic strategies: immune checkpoint inhibitors, cancer vaccines and adoptive
transfer of CAR-T cells, is reliant on a functionally active and tumour infiltrated CD8+ T cell population.
Currently, the use of these immunotherapeutic strategies has seen the most widespread clinical
benefit in the context of non-solid cancers and cancers with a non-prominent tumour stroma [91,92].
In solid tumours, which are characterised by a significant stromal reaction and abundance of CAFs,
the capacity of T-cells to kill cancer cells requires successful T cells recruitment, infiltration, and cytotoxic
function within the tumour. The purpose of this review is to give an overview of the literature
concerning different mechanisms by which CAFs can interfere with these three processes and ultimately,
prevent T-cell mediated tumour killing. As previously mentioned, large-scale depletion of the CAF
population has largely been shown to be deleterious to patient outcomes, exemplified by the failure
of clinical trials utilising this approach (NCT01130142). There is, therefore, an urgent clinical need
to develop novel therapeutics strategies that take a more nuanced approach when it comes to CAF
inhibition. Selective targeting of CAF functions that interfere with T cell recruitment, infiltration and/or
function in tumours is likely a more sensible alternative to large-scale CAF inhibition, and represents
an underappreciated clinical niche. Using a combinatory approach, inhibition of CAF functions
that interfere with T cells recruitment and function in tumours could unleash the full potential of
immunotherapies such as ICIs and CAR-T cells extending their use into the treatment of solid tumours.
Several strategies to overcome the inhibitory effects of CAFs on T-cells are beginning to emerge;
however, the field is still very much in its infancy. As previously discussed, IL-6 and CXCL12 are
two CAF-derived factors that impair T-cell function and recruitment to the TME [29,79]. Accordingly,
the clinical translatability of specific IL-6 and CXCL12 inhibitors has been evaluated in preclinical
models of melanoma and colorectal carcinoma [93,94]. In both studies, blockade of these CAF-derived
factors showed synergistic effects with anti-PD-1/PD-L1 therapy and increased the infiltration of CD8+
T cells within the TME. Interestingly, transcriptional profiling of these murine melanoma tumours
revealed an elevation of both cxcl9 and cxcl10 gene signatures upon combinatory blockade of IL-6
and PD-L1 [93]. These chemokines are known to orchestrate CD8+ T cell recruitment, and their lack
of expression is associated with limited infiltration of antigen specific T cells in various cancers [95]
including melanoma [96,97], dictating efficacy of adoptive T cell transfer in the latter [98]. Therefore,
selective blocking of CAF derived IL-6 in particular may represent a clinically relevant therapeutic
approach, with the potential to ameliorate both immune checkpoint inhibition and adoptive T
cell therapy through enhanced CD8+ T cell recruitment. Similarly, a recent study revealed that
the pharmacological blockade of NOX4, a ROS-producing enzyme with established roles in CAF
activation [99], sensitised murine models of lung, breast and colorectal cancer to both anticancer
vaccination and anti-PD-1 checkpoint inhibition through enhanced CD8+ T cell infiltration [100].
Importantly, Setanaxib, the selective small molecule inhibitor of NOX-4 has been subject to clinical
evaluation through phase II in the context of liver fibrosis (NCT03226067), displaying a favourable
safety profile; this compound could therefore be feasibly repurposed for treatment of CAF-rich,
immune-excluded tumours.
Overall, however, there is currently a rather limited body of work focused on therapeutically
exploiting CAF-mediated deregulation of CD8+ T cell function with this area of research needing
further attention in future studies.
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6. Conclusions and Future Perspectives
There is now a growing body of evidence detailing the mechanisms through which CAFs can
negatively regulate the activity of cytotoxic CD8+ T cells within the TME of solid malignancies.
As presented herein, this CAF mediated regulation of T cell function is mediated through interference
with T cell-recruitment, infiltration, and cytotoxic activity. Future studies must seek to further
characterise these molecular interactions between CAFs and CD8+ T cells. In particular, greater
emphasis needs to be made into delineating the precise role of CAF production of ECM components in
regulating T cell infiltration in the TME. As described, the jury is still out on whether deposition of
ECM serves to facilitate T cell infiltration or whether it forms a barrier to biophysically impede the
movement of T cells, as canonically believed to be the case.
Furthermore, future efforts must be made to build upon the basic science of CAF-T cell biology
presented within this review to facilitate the rational development of therapeutic strategies which
seek to target these interactions. Additionally, previous studies already showed that large-scale
genetic ablation of the CAF population as a whole is deleterious and translates to increased tumour
aggressiveness and reduced survival in preclinical studies [19,20], owing to the significant complexity
of CAF heterogeneity which is still far from being fully comprehended. While the search to better
understand CAF phenotypic heterogeneity is underway, we should simultaneously focus our efforts
into improving the clinical translatability of targeting CAF-T cell interactions. In theory, this will also
serve to ameliorate current immunotherapeutic treatment strategies such as adoptive T cell transfer,
immune checkpoint inhibitors and anticancer vaccination, extending their use in the treatment of a
wider range of solid malignancies.
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